Radiolabeling and Preclinical Evaluation of Therapeutic Efficacy of225Ac-ch806 in Glioblastoma and Colorectal Cancer Xenograft Models

The epidermal growth factor receptor (EGFR) protein is highly expressed in a range of malignancies. Although therapeutic interventions directed toward EGFR have yielded therapeutic responses in cancer patients, side effects are common because of normal-tissue expression of wild-type EGFR. We developed a novel tumor-specific anti-EGFR chimeric antibody ch806 labeled with